Benzinga · Oct 29, 2026
Canaccord Genuity Maintains Buy on Pharming, Raises Price Target to $41
Canaccord Genuity analyst Whitney Ijem maintains Pharming (NASDAQ:PHAR) with a Buy and raises the price target from $38 to $41.
PH
NASDAQ · PHAR
Pharming Group N.V.
Healthcare · Biotechnology
$12.93
Down-$0.34 (-2.59%)
Updated Nov 4, 2026, 4:47 PM
SID Score
4.4/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.2B
- P/E ratio
- 3,147.1
- Dividend yield
- 0.00%
- 52-week range
- $9.11 – $18.41
- Volume
- 21.64K
- Avg. volume
- 16.7K
Price performance · PHAR
PHAR price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
PHAR closed at $12.93 after 21 trading sessions, up 33.57% for the selected period.
- Last close
- $12.93
- Period change
- +33.57%
- Period low
- $9.11
- Period high
- $12.93
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $12.69 | $13.00 | $12.45 | $12.93 | 21.64K |
| Nov 2, 2026 | $12.75 | $12.75 | $12.455 | $12.73 | 19.96K |
| Oct 30, 2026 | $12.20 | $12.31 | $12.09 | $12.23 | 14.05K |
| Oct 29, 2026 | $12.25 | $12.27 | $11.75 | $12.13 | 12.42K |
| Oct 28, 2026 | $11.85 | $12.28 | $11.85 | $12.26 | 29.03K |
| Oct 27, 2026 | $12.01 | $12.1899 | $11.7646 | $11.87 | 19.19K |
| Oct 26, 2026 | $11.55 | $11.92 | $11.55 | $11.90 | 43.47K |
| Oct 23, 2026 | $11.32 | $11.45 | $10.76 | $11.20 | 25.78K |
| Oct 22, 2026 | $10.57 | $10.80 | $10.55 | $10.67 | 21.6K |
| Oct 21, 2026 | $9.47 | $9.73 | $9.45 | $9.65 | 10.92K |
| Oct 20, 2026 | $9.39 | $9.77 | $9.341 | $9.75 | 6.28K |
| Oct 19, 2026 | $9.315 | $9.34 | $9.11 | $9.11 | 13.37K |
| Oct 16, 2026 | $9.50 | $9.515 | $9.31 | $9.36 | 9.03K |
| Oct 15, 2026 | $9.50 | $10.03 | $9.50 | $9.63 | 7.34K |
| Oct 14, 2026 | $9.55 | $9.64 | $9.49 | $9.64 | 3.96K |
| Oct 13, 2026 | $9.62 | $9.62 | $9.32 | $9.44 | 28.94K |
| Oct 12, 2026 | $9.90 | $9.90 | $9.5608 | $9.61 | 7.51K |
| Oct 9, 2026 | $9.79 | $9.85 | $9.5248 | $9.79 | 3.33K |
| Oct 8, 2026 | $9.65 | $9.7716 | $9.4413 | $9.53 | 5.12K |
| Oct 7, 2026 | $9.65 | $9.75 | $9.59 | $9.65 | 3.83K |
| Oct 6, 2026 | $9.86 | $9.86 | $9.68 | $9.68 | 6.73K |
Latest PHAR news
The latest Smart Investors Daily articles mentioning PHAR.
Stock researchCompany · Overview
Company
Market Activity
Research & News
PHAR research
Overview
Company profile and research snapshot.
Company profile
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $42.00
- Implied upside
- —
- Analysts
- 14
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 23, 2026 | FIRST BERLIN EQUITY RESEARCH | Buy | — |
| Sep 22, 2026 | JEFFERIES | Buy | — |
| Jul 30, 2026 | OPPENHEIMER & CO., INC. | Outperform | — |
| Jul 13, 2026 | FIRST BERLIN EQUITY RESEARCH | Buy | — |
| Jul 12, 2026 | FIRST BERLIN EQUITY RESEARCH | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 28, 2026
Pharming Group (ENXTAM:PHARM) Stock Faces A Q3 Earnings Valuation Gap
Pharming Group entered its Q3 2026 earnings with a stretched reputation as a high-expectation biotech, trading on a P/E of 35.2x against a European peer average near half that. The fresh numbers show why believers stayed patient. Quarterly revenue reached US$117.6m and net income excluding one-off items came in at US$22.4m, a sharp profit recovery from earlier this year. Yet the stock closed at €1.08 on 27 October, leaving the 90 day return slightly in decline. That gap between rich...
Yahoo · Oct 27, 2026
Pharming (PHAR) Q3 2026 Earnings Call Transcript
Revenue grew 21% year-over-year as RUCONEST stabilized and Joenja expanded internationally.
Yahoo · Oct 27, 2026
Pharming Group Q3 Earnings Call Highlights
Pharming Group (NASDAQ:PHAR) reported third-quarter revenue growth of 21% to $117.6 million, supported by higher sales of its RUCONEST hereditary angioedema treatment and Joenja therapy for activated phosphoinositide 3-kinase delta syndrome, or APDS. Kenneth Lynard, interim co-CEO and chief financi
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
